Industry News

QIAGEN Enters into Agreement to Acquire STAT-Dx

By Labmedica International staff writers
13 Feb 2018

Image: Qiagen plans to acquire diagnostics developer STAT-Dx for up to $191 million, in a deal designed to facilitate the buyer's planned launch later this year of the QIAstat-Dx platform, based on STAT-Dx’s proprietary DiagCORE technology (Photo courtesy of STAT-Dx).QIAGEN N.V. (The Netherlands) has entered into an agreement to acquire STAT-Dx (Barcelona, Spain), a privately-held company which develops next generation of multiplex diagnostics for one-step, fully integrated molecular analysis of common syndromes using a novel system based on real-time PCR technology and proven QIAGEN chemistries.

The system, which will be branded as QIAstat-Dx, enables scalable Sample to Insight processing of up to 48 molecular targets simultaneously for diagnosing syndromes, such as serious respiratory or gastrointestinal infections, as well as for use in oncology. With cost-efficient, easy-to-use assays suitable for any clinical sample type, the system can provide qualitative as well as quantitative insights into the precise cause of various syndromes in about one hour.

Based on the proprietary DiagCORE technology, the system received a first CE-IVD marking in January 2018. The system utilizes cost-efficient, single-use cartridges with built-in sample processing and all reagents on board. The cartridges are loaded with QIAGEN sample and assay technologies and a lab technician only needs to load a clinical sample into a cartridge and place it in the analyzer, requiring less than one minute of hands-on time.

The flexible modular system, which has bi-directional LIS (laboratory information system) interface capabilities, is designed to operate in a range of near-patient clinical settings, eliminating the delay of sending samples to a centralized laboratory. The cartridges are processed in a scalable, proprietary and fully integrated platform, which can be configured from one to eight modules, independently running cartridges with predefined assay protocols and managed via a touchscreen that offers simple step-by-step directions.

QIAstat-Dx is planned to be further developed with the aim of becoming the first analyzer that combines capabilities to run the highest multiplexing molecular diagnostic assays with the ability to quantitate and also process immunoassays. The first two tests, which are extensive respiratory and gastrointestinal (GI) panels, are to be launched in Europe in the second half of 2018, in the US in 2019 following regulatory clearance, and in other markets worldwide. Additional tests are under development for infectious diseases, immune response monitoring, oncology and companion diagnostics.

“QIAstat-Dx represents the next generation of innovation for multiplex syndromic testing, using powerful QIAGEN technologies and a real-time PCR technology that will allow for a much broader range of applications and drive the dissemination of molecular testing. The system is designed for significantly more cost-efficient test processing as required by the current reimbursement environment. Additional application areas for this system include companion diagnostics, quantitative analysis and immunoassay tests, offering customers a new level of flexibility and accurate diagnosis designed to support better outcomes for patients and healthcare systems,” said Peer M. Schatz, Chief Executive Officer of QIAGEN N.V. “We look forward to adding QIAstat-Dx to our portfolio of Sample to Insight solutions. This is further confirmation as to how we are leveraging our advantages in sample and assay technologies, our leadership in providing solutions for infectious disease testing and the global reach of our commercial teams.”

“We are excited about accelerating the commercialization of our technology to bring fast, cost-effective syndromic testing closer to care for patients and healthcare providers. At the closing of the transaction, we will build on the achievements of our fantastic team in developing a best-in-class system and leverage QIAGEN’s resources with extensive R&D and commercial reach around the world,” said Jordi Carrera, co-founder and Chief Executive Officer of STAT-Dx.



E-mail Print
FaceBook Twitter Google+ Linked in

QIAGEN

Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including complete kits for pre-defined applications in sample preparation and analysis, and individual enzymes and reagents. It also offers instruments for automating the full range of laboratory procedures, from the initial sample preparation to the final test result.
More info

More articles about QIAGEN

20 May 2022
Qiagen Acquires Enzymes Provider Blirt to Strengthen Sample Technologies Business
QIAGEN N.V. (Venlo, Netherlands) has signed agreements to acquire a 96% majority ownership stake in BLIRT S.A. (Gdansk, Poland), a manufacturer of recombinant enzymes for the life science industry.
Read More
02 Jul 2021
Qiagen Partners with Sysmex for Development and Commercialization of Cancer Companion Diagnostics
QIAGEN N.V. (Venlo, Netherlands) and Sysmex Corporation (Kobe, Japan) have entered into a global strategic alliance for the development and commercialization of cancer companion diagnostics, which will leverage both QIAGEN’s leadership in this field and Sysmex’s Plasma-Safe-SeqS technology for next generation sequencing (NGS).
Read More
14 Aug 2020
QIAGEN to Focus on Molecular Testing amidst Coronavirus Pandemic after Voluntary Public Takeover Offer by Thermo Fisher Falls Short
QIAGEN N.V. (Venlo, Netherlands) plans to continue executing its growth strategy aimed at creating significant value for shareholders and other stakeholders after the voluntary public takeover offer by Thermo Fisher Scientific Inc. (Waltham, MA, USA) failed to achieve the minimum 66.67% acceptance threshold from QIAGEN shareholders.
Read More
12 Jan 2017
Qiagen Acquires Bioinformatics Firm OmicSoft
QIAGEN N.V., a provider of sample and assay technologies, has acquired OmicSoft Corporation, which focuses on biomarker data management, visualization, and analysis.
Read More

Additional news

16 Aug 2022
BD and Accelerate Diagnostics Collaborate to Offer Rapid Antimicrobial Identification and Susceptibility Diagnostics
Becton, Dickinson and Company (BD, Franklin Lakes, NJ, USA) and Accelerate Diagnostics, Inc. (Tucson, AZ, USA) have entered into a worldwide commercial collaboration agreement where BD will offer Accelerate's rapid testing solution for antibiotic resistance and susceptibility offering results in hours, versus one to two days with some traditional laboratory methods.
Read More
05 Aug 2022
Bio-Rad Acquires Curiosity Diagnostics from Scope Fluidics
Bio-Rad Laboratories (Hercules, CA, USA) has reached an agreement to acquire all of the outstanding shares of Curiosity Diagnostics, Sp. Z. o. o. from Scope Fluidics, S.A. (Warsaw, Poland) for a total consideration of up to USD 170 million, consisting of approximately USD 100 million in cash, and up to USD 70 million in future milestone payments.
Read More
04 Aug 2022
Capsule Endoscopy System Market Driven by Rising Preference for Minimally Invasive Screening Procedure
The global capsule endoscopy system market is expanding at a rapid pace due to the rising demand for the procedure using minimally invasive diagnostic techniques, increase in the introduction of technologically advanced capsules, growth in the geriatric population, and rising prevalence of cancer around the world.
Read More
02 Aug 2022
PerkinElmer Divests Other Businesses to Focus on Life Sciences and Diagnostics
PerkinElmer, Inc. (Waltham, MA; USA) has entered into an agreement with the intention to divest its Applied, Food and Enterprise Services businesses to New Mountain Capital (New York, NY, USA) for total consideration of USD 2.45 billion in cash.
Read More
31 Jul 2022
Labcorp to Spin Off Clinical Development Business
LabCorp Diagnostics (Burlington, NC, USA) has announced that its board of directors has authorized the company to pursue a spin-off of its wholly owned Clinical Development business to shareholders through a tax-free transaction.
Read More
31 Jul 2022
IFCC Celebrates 70 Years of Advancing Science of Laboratory Medicine and In Vitro Diagnostics
The IFCC is celebrating 70 years (1952 – 2022) of enormous achievements that have been extraordinary and impressive, contributing to its mission of “Advancing excellence in laboratory medicine for better healthcare worldwide”.
Read More
27 Jul 2022
Medlab Asia and Asia Health to Host First-Ever Live, In-Person Event in Thailand
Informa Markets (London, UK), in partnership with Impact Muang Thong Thani (Nonthaburi, Thailand), have confirmed that Medlab Asia and Asia Health will take place in Thailand for the first time when the co-located events return live and in-person at the Impact Exhibition Center, Bangkok, from 19-21 October 2022.
Read More
25 Jul 2022
Registration Opens for RSNA 2022
Registration is now open for the Radiological Society of North America’s (RSNA, Oak Brook, IL, USA) 108th Scientific Assembly and Annual Meeting to be held at McCormick Place Chicago, Nov. 27 – Dec. 1, 2022.
Read More
25 Jul 2022
Bioperfectus and ELITechGroup Collaborate for Monkeypox Virus Testing Across Europe
Jiangsu Bioperfectus Technologies Co., Ltd. (Shanghai, China) and ELITechGroup S.p.A. (Puteaux, France) have entered into a strategic partnership for monkeypox virus testing across Europe.
Read More
Copyright © 2000-2022 TradeMed.com. All rights reserved. | Terms And Conditions